Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Other Accumulated Expenses (2016 - 2025)

Palisade Bio (PALI) has disclosed Other Accumulated Expenses for 14 consecutive years, with $211000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 10.21% to $211000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $211000.0, a 10.21% decrease, with the full-year FY2024 number at $79000.0, down 56.59% from a year prior.
  • Other Accumulated Expenses was $211000.0 for Q3 2025 at Palisade Bio, down from $260000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $349000.0 in Q2 2024 to a low of $11000.0 in Q2 2022.
  • A 5-year average of $176111.1 and a median of $182000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 86.25% in 2022, then fell 10.21% in 2025.
  • Palisade Bio's Other Accumulated Expenses stood at $80000.0 in 2021, then plummeted by 86.25% to $11000.0 in 2022, then soared by 1554.55% to $182000.0 in 2023, then plummeted by 56.59% to $79000.0 in 2024, then skyrocketed by 167.09% to $211000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Other Accumulated Expenses are $211000.0 (Q3 2025), $260000.0 (Q2 2025), and $79000.0 (Q4 2024).